PTGX
Price
$53.40
Change
+$1.87 (+3.63%)
Updated
Jun 5, 12:45 PM (EDT)
Capitalization
3.19B
56 days until earnings call
TRVI
Price
$6.54
Change
-$0.05 (-0.76%)
Updated
Jun 5, 12:49 PM (EDT)
Capitalization
669.48M
63 days until earnings call
Interact to see
Advertisement

PTGX vs TRVI

Header iconPTGX vs TRVI Comparison
Open Charts PTGX vs TRVIBanner chart's image
Protagonist Therapeutics
Price$53.40
Change+$1.87 (+3.63%)
Volume$200
Capitalization3.19B
Trevi Therapeutics
Price$6.54
Change-$0.05 (-0.76%)
Volume$1.15K
Capitalization669.48M
PTGX vs TRVI Comparison Chart
Loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTGX vs. TRVI commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a Buy and TRVI is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (PTGX: $51.53 vs. TRVI: $6.58)
Brand notoriety: PTGX and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 67% vs. TRVI: 522%
Market capitalization -- PTGX: $3.19B vs. TRVI: $669.48M
PTGX [@Biotechnology] is valued at $3.19B. TRVI’s [@Biotechnology] market capitalization is $669.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 2 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • PTGX’s FA Score: 2 green, 3 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, PTGX is a better buy in the long-term than TRVI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 5 TA indicator(s) are bullish while TRVI’s TA Score has 6 bullish TA indicator(s).

  • PTGX’s TA Score: 5 bullish, 4 bearish.
  • TRVI’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, TRVI is a better buy in the short-term than PTGX.

Price Growth

PTGX (@Biotechnology) experienced а +12.63% price change this week, while TRVI (@Biotechnology) price change was +5.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.05%. For the same industry, the average monthly price growth was +10.91%, and the average quarterly price growth was -1.52%.

Reported Earning Dates

PTGX is expected to report earnings on Jul 31, 2025.

TRVI is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+5.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($3.19B) has a higher market cap than TRVI($669M). TRVI YTD gains are higher at: 59.709 vs. PTGX (33.497). PTGX has higher annual earnings (EBITDA): 30.1M vs. TRVI (-47.23M). PTGX has more cash in the bank: 574M vs. TRVI (103M). TRVI has less debt than PTGX: TRVI (957K) vs PTGX (11.4M). PTGX has higher revenues than TRVI: PTGX (208M) vs TRVI (0).
PTGXTRVIPTGX / TRVI
Capitalization3.19B669M477%
EBITDA30.1M-47.23M-64%
Gain YTD33.49759.70956%
P/E Ratio66.06N/A-
Revenue208M0-
Total Cash574M103M557%
Total Debt11.4M957K1,191%
FUNDAMENTALS RATINGS
PTGX vs TRVI: Fundamental Ratings
PTGX
TRVI
OUTLOOK RATING
1..100
197
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
4558
SMR RATING
1..100
2794
PRICE GROWTH RATING
1..100
3836
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (56) in the Pharmaceuticals Major industry is in the same range as PTGX (79) in the Biotechnology industry. This means that TRVI’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (45) in the Biotechnology industry is in the same range as TRVI (58) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to TRVI’s over the last 12 months.

PTGX's SMR Rating (27) in the Biotechnology industry is significantly better than the same rating for TRVI (94) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew significantly faster than TRVI’s over the last 12 months.

TRVI's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as PTGX (38) in the Biotechnology industry. This means that TRVI’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for TRVI (100) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew significantly faster than TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXTRVI
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 23 days ago
78%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TAVFX63.03N/A
N/A
Third Avenue Value Instl
OSCCX19.73N/A
N/A
Invesco Main Street Small Cap C
NWHNX10.97N/A
N/A
Nationwide Bailard Intl Eqs Instl Svc
UBVVX80.06N/A
N/A
Undiscovered Managers Behavioral Val R5
FULVX12.41N/A
N/A
Fidelity U.S. Low Volatility Equity